Biomarker and Genetic Predictors of Erenumab Treatment Response
NCT04265755
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
1406
Enrollment
INDUSTRY
Sponsor class
Conditions
Migraine
Interventions
DRUG:
Erenumab
Sponsor
Amgen